Statement of Principles concerning diabetes mellitus (Reasonable Hypothesis) (No. 48 of 2020)

The instrument centres on a few core legal and medical concepts: the statutory reasonable hypothesis test, a tightly specified clinical definition of diabetes mellitus, a closed list of qualifying factors with quantitative thresholds, temporality linking factor to clinical onset or worsening, and the requirement that factors be related to relevant service. The statement frames diabetes mellitus not as a single undifferentiated category, but as a set of clinical entities with subtype distinctions that matter for which factors are applicable and what timing is relevant (s 7(2), s 9).

Definition of the disease: diabetes mellitus is defined by discrete laboratory criteria: either two positive tests on separate days with either (1) fasting plasma glucose ≥ 7.0 mmol/L, or (2) plasma glucose ≥ 11.1 mmol/L two hours after 75 g oral glucose load, or (3) HbA1c ≥ 6.5 per cent; or an episode of diabetic ketoacidosis or hyperosmolar hyperglycaemic state with blood glucose ≥ 11.1 mmol/L (s 7(2)(a)(i)-(ii)). The instrument further sets out that the legal meaning is the statutory definition, not simply the ICD code (s 7(3)-(4)). Death from diabetes mellitus is captured where a terminal event or condition was contributed to by the person's diabetes (s 7(5); Schedule definition of terminal event).

Factors and thresholds: s 9 enumerates factors that "must as a minimum exist" for a reasonable hypothesis to be raised. The list is granular. Examples of threshold‑based factors include: defined glucocorticoid therapy where cumulative dose or inhaled equivalent meets a Schedule threshold and, if therapy has ceased or decreased, the last dose was within 30 days before clinical onset (s 9(3), Schedule definitions for "glucocorticoid therapy as specified", "equivalent glucocorticoid therapy", and the dosing table). Drug exposure thresholds include continuous treatment with a drug from Specified List 1 for at least seven days prior to onset, or antidepressant/antipsychotic class treatment for at least six weeks (s 9(4)-(5); Specified List 1 in the Schedule). For type 1 diabetes, certain pancreatic surgeries, splenectomy for trauma, radiation involving the pancreas, specified pancreatic pathological conditions, haemolytic uraemic syndrome, ingestion of Vacor within 30 days, immune checkpoint inhibitors or interferons within one year, and Coxsackie B infection within three years are listed (s 9(6)(a)-(h)). For type 2 diabetes there are lifestyle, metabolic and toxic exposures with minimum durations: smoking at least five pack‑years with a 15‑year cessation window, 5,000 hours of second‑hand smoke exposure with a 15‑year cessation window, being overweight or obese for at least five years (Schedule provides BMI and waist circumference criteria), inability to undertake moderate physical activity of at least four METs for five years, liver disease, HIV or hepatitis C, hypertension, chronic renal failure, gout or hyperuricaemia, certain psychiatric disorders at time of onset, bilateral orchiectomy, anti‑androgen therapy for at least one year, arsenic exposure meeting specified criteria, TCDD contaminated chemical exposure with cumulative 500 hours in a ten year period and timing rules, and inability to breast feed cumulatively six months for parous women (s 9(7)(a)-(t), Schedule).

Temporal and relational concepts: the instrument distinguishes clinical onset and clinical worsening between separate parts of s 9. It provides time‑bounded windows linking exposures to onset or worsening and, in some cases, to cessation (for example, smoking cessation within 15 years; TCDD exposure ceased and onset within 25 years) (s 9(7)(a) and s 9(7)(s)). Section 10(1) requires that any factor be related to the person's relevant service. Section 10(2) restricts certain factors to only material contribution or aggravation where the diabetes pre‑existed or was suffered or contracted before or during (but did not arise out of) service.

Cross‑references and definitional economy: the Schedule is extensive and defines operational terms such as BMI, MET, one pack‑year, the Specified Drug Lists, specified endocrine disorders, and the detailed operational definition of TCDD exposure (Schedule items). Section 11 requires that where a factor in s 9 refers to an injury or disease for which a separate SOP exists, the terms of that other SOP apply as in force from time to time.

Evidence standard and purpose statement: the RMA's view that there is sound medical‑scientific evidence is set out as the authority for the factors (s 8). That statement identifies the instrument as an evidence‑informed tool for linkage in decision making rather than a free‑standing entitlement provision.

In short, the main concepts are precise clinical thresholds, enumerated causal or contributing factors with quantitative or timing thresholds, subtype differentiation, and the requirement that factors be tied to relevant service for the specified legal test under the VEA or MRCA.

Primary affected persons are applicants making claims under s 120A of the VEA or s 338 of the MRCA, because the instrument applies expressly to claims to which those sections apply (s 5). Those applicants will include veterans, members of peacekeeping forces, and members of the Forces as defined under VEA and MRCA, since the RMA states the instrument relates to those who rendered relevant service (s 8; Schedule definition of relevant service). The term relevant service is defined in the Schedule to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule).

Decision makers and administrators are directly affected: the instrument is a Statement of Principles made under the Repatriation Medical Authority's statutory power (s 3). It is used by decision makers within the Department of Veterans' Affairs and adjudicative bodies applying the reasonable hypothesis test under the quoted provisions of the VEA and MRCA. Those officials will apply the definitions, thresholds and relational rules in the SOP to determine whether the statutory threshold for a reasonable hypothesis is met.

Medical practitioners and expert witnesses are affected practically, because their clinical records and opinions will be assessed against the specific laboratory thresholds (s 7(2)), exposure durations and dose metrics set out in the Schedule and s 9. For example, practitioners will need to supply evidence of cumulative glucocorticoid doses, the precise nature of pancreatic surgery, or pack‑year calculations consistent with the Schedule's definition of one pack‑year.

Any party who relies on another SOP is affected by s 11. Where a factor in s 9 refers to an injury or disease covered by a different SOP, the terms of that other SOP apply, and practitioners advising claimants must consult those other instruments as in force (s 11).

Families and dependants asserting death benefits could be affected because s 7(5) includes death from diabetes mellitus where a terminal event or condition was contributed to by the person's diabetes. This expands the instrument's reach to fatal outcomes where diabetes is a contributing factor, provided the causal and temporal rules in s 9 and s 10 are met.

The instrument also affects record‑keepers and employers in a practical way. Certain qualifying factors require workplace or environmental exposure evidence, for example inhaling, ingesting, or cutaneous contact with TCDD‑contaminated agents for cumulative 500 hours within ten years (s 9(7)(s); Schedule definition of TCDD contact). Those seeking to demonstrate such exposures will require precise contemporaneous records or credible reconstructions.

Finally, the instrument affects legal and clinical advisers preparing claims because of its precise thresholds and its interaction with other SOPs; advisers must marshal evidence to the specific metrics in the Schedule and tie those factors to the person's relevant service as required by s 10(1).

This instrument does not itself create new civil or criminal duties or penalties. Its operative legal effect is to specify what medical and exposure factors, when present and related to relevant service, satisfy the Repatriation Medical Authority's view of the medical‑scientific evidence necessary to raise a reasonable hypothesis connecting diabetes mellitus or death from diabetes mellitus to service. The key legal duties and rights flow from that operative effect when applied under the VEA and MRCA claims processes.

Right to have a claim assessed with these criteria: a person who lodges a claim under the sections of the VEA or MRCA identified in s 5 has the right to have their claim assessed using the criteria in this SOP, because the instrument is made under s 196B(2) of the VEA and applies to those claims (s 3, s 5). The SOP establishes the evidential criteria that decision makers will apply for the reasonable hypothesis stage.

Duty to demonstrate a qualifying factor and linkage to relevant service: for the SOP to assist in establishing a reasonable hypothesis, at least one of the factors in s 9 must exist (s 9). Section 10(1) makes a further thresholding duty explicit: the existence of any s 9 factor "must be related to the relevant service rendered by the person" for the SOP to raise the reasonable hypothesis. Thus the claimant carries the practical burden of adducing evidence showing the factor existed and that it relates to the person's relevant service, although the statutory allocation of legal burdens within the VEA/MRCA processes is not re‑stated in this instrument.

Temporal duties: several factors have explicit timing and duration requirements in s 9 and the Schedule. For example, glucocorticoid therapy as specified must have ceased or decreased such that the last dose was within 30 days before clinical onset when therapy has ceased or decreased (s 9(3)); Specified List 1 drug treatment must have been for at least seven days before clinical onset (s 9(4)); antidepressant or antipsychotic treatment must have been for at least six weeks (s 9(5)); smoking must amount to at least five pack‑years and, if permanently ceased, the onset must be within 15 years of cessation (s 9(7)(a)). Claimants and advisers must therefore locate and present medical, pharmacy and service records that align to these temporal rules.

Cross‑reference duty: where a factor in s 9 refers to an injury or disease covered by another SOP, s 11 requires that the factors in that other SOP apply according to its terms. Practically, that means decision makers and claimants must consult the other SOP when evidence points to such cross‑referenced conditions.

Right to have death considered: s 7(5) extends the instrument's application to death from diabetes mellitus where a terminal event or condition was contributed to by the person's diabetes mellitus. This is a substantive right for dependants or estates to have fatal outcomes considered under these criteria.

There is no penalty regime in the instrument. It contains no provision for sanctions, fines or criminal enforcement for non‑compliance. Its enforcement is administrative: it supplies criteria used in statutory decision making under the VEA and MRCA; compliance duties arise from the claimant's need to provide evidence to meet the SOP thresholds, and from decision makers' duty to apply the SOP where the relevant statutory test arises.

Finally, because the instrument is an administrative SOP, affected parties have whatever procedural rights and review avenues exist under the VEA and MRCA claims and review processes, but those processes are not set out in this instrument. The instrument is a binding tool for decision makers in the sense that it specifies the RMA's view of the medical‑scientific relationships, and it therefore influences entitlement outcomes where the statutory reasonable hypothesis test is the operative standard.

The Statement of Principles itself contains no penalty provisions and does not create criminal or civil sanctions. The instrument is regulatory in the sense of setting evidentiary benchmarks and causal criteria; its legal effect is to be applied in administrative decision making under the VEA and MRCA. The text contains no enforcement mechanisms, infringement notices, or penalty schedules. The only legally operative enforcement is indirect: decision makers will accept or reject claims for entitlements under the statutory frameworks (the VEA and MRCA) in reliance on whether the medical and exposure criteria in this SOP, and their relation to relevant service, are satisfied.

Consequently, the practical effects resembling enforcement are procedural and administrative. If, on the evidence, no factor from s 9 exists or any factor is not related to relevant service, the reasonable hypothesis threshold will not be raised and the claim may be rejected at that stage within the claims process governed by the VEA or MRCA. The SOP thereby functions as a gatekeeping tool which can determine access to subsequent entitlements, but it does so via decision making under the parent Acts, not by imposing fines or criminal liability.

Who enforces in practice: the Repatriation Medical Authority makes the SOP under its statutory power (s 3), and decision makers within the Department of Veterans' Affairs or other bodies applying s 120A VEA or s 338 MRCA will use it. The instrument does not itself authorise any agency to impose penalties; rather it provides the medical criteria relevant to entitlement determinations. Any challenge to decisions applying the SOP will proceed under the review and merits/ judicial review mechanisms available in the VEA and MRCA regimes, but those procedures and potential remedies are not set out in this instrument.

Proof, evidence and administrative consequence: the instrument creates precise thresholds and timing rules that will be the focal point for evidentiary disputes. For example, if a claimant asserts glucocorticoid therapy met the Schedule thresholds, records must show cumulative dose and average dose rates in accordance with the table in the Schedule. If records fall short, administrative decision makers may find the factor is not established and thereby decline to find a reasonable hypothesis. Similarly, exposures requiring cumulative hours (for example TCDD contamination, s 9(7)(s) and Schedule definition) will require documentary or credible contemporaneous evidence; absence of such evidence will have the practical enforcement consequence of a negative decision.

No power to alter other laws: the instrument does not purport to amend or displace other statutes. It references ICD‑10‑AM coding for classification purposes (s 7(3)-(4)). It also cross‑references other Statements of Principles where relevant factors overlap (s 11), instructing decision makers to apply the other SOPs as in force.

In sum, enforcement is exercised through administrative application in the claims process. The SOP sets binding criteria for the reasonable hypothesis stage, but there are no direct penalties in the instrument itself; the "sanction" for failure to meet the SOP criteria is administrative denial of the relevant claim under the VEA or MRCA.

The instrument explicitly situates itself within the VEA and MRCA framework. It is made under subsection 196B(2) of the VEA (s 3) and applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). It therefore operates as an evidentiary tool within the statutory decision‑making frameworks established by those Acts. The instrument does not itself amend or repeal provisions of the VEA or MRCA, nor does it set out benefits or procedural rules; those remain the domain of the parent statutes. Decision makers applying the VEA or MRCA will use this SOP to assess the reasonable hypothesis element of entitlement.

Cross‑SOP interaction: s 11 provides a mechanism for interplay with other Statements of Principles. If a factor in s 9 refers to an injury or disease that is the subject of another SOP determined under subsection 196B(2) of the VEA, then the factors in that other SOP apply according to its terms as in force from time to time. This creates a textual hierarchy where s 9 can invoke other SOPs, and decision makers must consult those instruments for any factor that is defined elsewhere. Practically, this means a claimant with a cross‑referenced condition cannot rely solely on the diabetes SOP; the decision maker will apply the separate SOP for the referenced condition.

Classification and medical coding: s 7(3)-(4) clarifies the relation to ICD‑10‑AM coding. While diabetes mellitus in ICD‑10‑AM may have codes E10-E14, the instrument makes clear the operative legal definition is the one in s 7(2). The instrument also identifies the edition and effective date of the ICD‑10‑AM and its source (Tenth Edition, effective 1 July 2017), which could matter where coding is used to match medical records or to trigger cross‑references to the broader classification system.

Relevant service and other statutory definitions: the Schedule defines "relevant service" to include specified service categories under the VEA and MRCA. This ties the SOP to the statutory definitions in the parent Acts, and means the determination of whether the service is relevant requires reference to those Acts. The SOP thus interacts procedurally with how VEA and MRCA define operational, hazardous, peacekeeping, warlike and non‑warlike service.

Amendments and legislative history: Endnotes 3 and 4 set out the instrument's amendment history, listing the original Statement (No. 48 of 2020) and subsequent amendments No. 83 of 2021, No. 49 of 2022, and an amendment to the definition of "one pack‑year" in No. 94 of 2022 (Endnote 3). The amendment history references specific changes to subsections and Schedule entries (Endnote 4). Those amendments interact with other legislation only in the sense that they update the SOP's content and will be applied by decision makers in place of prior text when assessing claims.

No prescriptive overlap with general workplace health and safety or compensation statutes is stated in the instrument. The SOP is focused on VEA/MRCA claims. It does not purport to alter obligations under workplace compensation, public health, environmental, or criminal laws that may also be implicated by exposures such as TCDD or arsenic. For example, the Schedule defines exposures to TCDD‑contaminated chemical agents in occupational terms, but the SOP does not displace any employer liability or regulatory obligations under environmental or occupational statutes.

Administrative review and judicial processes: while the SOP does not itself specify appeal or review routes, its role in administrative decision making under the VEA and MRCA will mean that decisions applying it are subject to the review and judicial oversight mechanisms provided in those Acts. The instrument instructs decision makers on the technical medical criteria, but substantive legal questions about application and procedural fairness remain addressed by the parent Acts' processes.

In summary, the SOP interacts with other laws by being a medical‑scientific substrate for decision making under the VEA and MRCA, by cross‑referencing other SOPs under the same statutory regime, by identifying ICD classification for medical record purposes, and by relying on statutory definitions of relevant service. It does not create duties under other legislative regimes nor does it prescribe remedies or penalties outside the administrative claim processes.

The compilation includes a history of the instrument's amendments in the endnotes. The original Statement of Principles concerning diabetes mellitus (No. 48 of 2020) was registered on 29 June 2020 and commenced on 27 July 2020 (Endnote 3). Subsequent amending determinations are recorded as follows (Endnote 3):

• Amendment Statement of Principles concerning diabetes mellitus (No. 83 of 2021), registered 30 June 2021, commenced 26 July 2021.
• Amendment Statement of Principles concerning diabetes mellitus (No. 49 of 2022), registered 2 May 2022, commenced 30 May 2022.
• Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022), registered 26 August 2022, commenced 19 September 2022.

Endnote 4 provides a provision‑level amendment table indicating how particular sections were changed across those amending instruments. The amendment history shows specific adjustments, additions and re‑statements to subsections and Schedule definitions. Items recorded in Endnote 4 include:

• Repeals and amendments to earlier internal section numbering (for example, Section 2 and Section 4 entries marked "rep LA s 48D" and "rep LA s 48C" reflecting legislative housekeeping).
• Changes to subsection 9(6)(g) and 9(6)(h) across amending instruments (rs No. 83 of 2021; am No. 83 of 2021; rs No. 49 of 2022), showing that the provisions dealing with immune checkpoint inhibitors and Coxsackie B virus infection were revised by the 2021 and 2022 amendments.
• Addition of subsection 9(13a) in the 2021 amending determination and its subsequent revision in the 2022 determination (ad No. 83 of 2021; rs No. 49 of 2022).
• Addition of the definition "immune checkpoint inhibitor" to the Schedule by No. 49 of 2022 (ad No. 49 of 2022).
• Revisions to notes and the Schedule definitions for "one pack‑year" and related notes effected by No. 94 of 2022 (rs No. 94 of 2022).

The endnotes therefore show active maintenance of the SOP, with substantive edits to exposure definitions and the addition of specific pharmacological categories. The amendment entries identify which subsections were added, revised or restated, though the compilation itself incorporates these amendments up to F2022L01128 as of the compilation date 19 September 2022.

Practically, the amendment history indicates that decision makers and advisers must ensure they are applying the SOP as in force at the time of claim assessment. Section 11 reinforces that other SOPs in force apply to their referenced factors. The changes, particularly to drug‑related items (immune checkpoint inhibitors, interferons) and to the definition of "one pack‑year", reflect technical updates to ensure the Schedule and exposure thresholds capture evolving medical practice and terminological clarity.

The endnotes also explain that the compilation includes notes about uncommenced amendments, modifications, and application, saving and transitional provisions where applicable. For a user of this SOP, the amendment history means checking the specific instrument number and its commencement date to confirm which version of the SOP applies to a particular claim, and verifying that any cross‑referenced SOPs are likewise current.

No retrospective or transitional application rules are stated in the body of this instrument; practitioners should consult the legislation register and the parent Acts for any transitional provisions or commencement particulars beyond those recorded in the endnotes.

The compiled instrument and its endnotes do not record any litigation history. The endnotes supply amendment and registration history, but they do not list judicial decisions or administrative appeals that interpret this Statement of Principles. There are no cases or determinations named in the instrument text or the endnotes.

That absence in the compilation does not, by itself, indicate whether decisions applying this SOP have or have not been the subject of review or appeal under the VEA or MRCA avenues. The SOP is designed to be applied within claim decision processes under s 120A of the VEA or s 338 of the MRCA (s 5), and decisions made under those Acts are generally subject to the statutory review, merits review or judicial review mechanisms those Acts provide, but the compilation does not reproduce those mechanisms nor does it record any case law. The instrument therefore standing alone contains no litigation precedents or judicial interpretations to cite.

For practitioners, that means two things in concrete terms. First, reliance on the SOP for claim preparation and decision making must be based on the text and the Schedule definitions as currently in force, rather than on any incorporated case law or precedent within the instrument. Second, if contested in administrative or judicial review, questions of statutory interpretation, the nature of "clinical onset", "clinical worsening", the sufficiency of evidence showing exposure thresholds, or the causative linkage to service are likely to be the issues argued in decision review proceedings; however those are analytical observations based on the instrument's content and the role it plays in statutory decision making, not reported litigation outcomes within the instrument.

Because the SOP cross‑references other SOPs (s 11), litigation or review that has addressed related SOPs might have indirect relevance, but such materials are not contained in this instrument. Practitioners and decision makers seeking authoritative interpretive guidance should therefore consult the VEA and MRCA decision records, merits review tribunal determinations, or judicial decisions external to this instrument where available, and check whether any particular application of this SOP has been the subject of published administrative or judicial review. The compilation's endnotes do not list such items.

The instrument's technical density and specific thresholds create a number of practical pitfalls for claimants, clinicians, and advisers. These "gotchas" are concrete, textually grounded traps or points of friction that commonly affect the success of a claim if not anticipated.

1. Clinical definition vs ICD code. The SOP makes clear that, although diabetes mellitus is associated with ICD‑10‑AM codes E10-E14, the legal meaning for this SOP is the clinical definition in s 7(2) (s 7(3)). Practitioners cannot rely on ICD coding alone; they must produce evidence satisfying the laboratory thresholds or episode definitions in s 7(2). A record showing an ICD code without documentation of two positive laboratory tests or a qualifying acute episode may be insufficient.

2. Requirement of two positive tests on separate days. The diagnostic rule in s 7(2)(a)(i) requires two positive laboratory blood tests on separate days for the specified measures, or alternatively an acute metabolic episode under s 7(2)(a)(ii). Single test results or non‑standard tests will not meet the statutory definition.

3. Precise laboratory thresholds matter. The SOP uses numeric cutoffs: fasting plasma glucose ≥ 7.0 mmol/L, 2‑hour glucose ≥ 11.1 mmol/L after 75 g load, HbA1c ≥ 6.5 per cent, or blood glucose ≥ 11.1 mmol/L during a qualifying acute episode. Small differences in reported values or laboratory variability can therefore change whether the statutory definition is met.

4. Subtype‑specific factors. Many factors in s 9 are specific to type 1, type 2 or gestational diabetes. Advisers must match pleaded factors to the correct diabetes subtype. For instance, pancreatic surgery or Vacor ingestion are factors for type 1 only (s 9(6)), whereas pack‑year smoking and certain metabolic comorbidities are in s 9(7) for type 2.

5. Temporal windows and cessation rules. Several factors have strict timing rules. For smoking, permanent cessation leaves a 15‑year window (s 9(7)(a)). For TCDD exposure there are cumulative hour requirements and a 25‑year cessation window if exposure has ceased (s 9(7)(s)). Glucocorticoid therapy cessation requires that the last dose was within 30 days before clinical onset if therapy ceased or decreased (s 9(3)). Failure to document timing accurately risks failing the SOP test.

6. Cumulative dose and dose‑rate complexities for glucocorticoid therapy. The Schedule sets minimum cumulative doses and average daily rates for named glucocorticoids, and provides equivalence rules. Practitioners must compute cumulative doses and average daily rates consistent with the table and consider equivalence if another glucocorticoid was used. Records that show only prescription names without dosing schedules or cumulative totals may be insufficient.

7. Drug lists are closed and technical. The Specified List 1 and Specified List 2 in the Schedule enumerate multiple agents. A claim that a particular drug contributed to diabetes must show the drug is on the list and that the minimum duration rules are met (s 9(4), s 9(12)). Newer drugs not on the list or off‑label exposures may not be covered unless the lists are amended.

8. Cross‑referenced SOPs. If a factor points to an injury or disease covered by another SOP, the decision maker will apply that other SOP (s 11). Claimants and advisers must identify and review those other SOPs, which may have different thresholds or timing rules.

9. "Related to relevant service" is a legal link distinct from mere exposure. Section 10(1) requires the factor to be related to relevant service. That is an additional connection beyond proving the existence of a factor; evidence must link the exposure or event to the person's service as defined in the Schedule.

10. Material contribution and aggravation limitation. Subsections 9(9) to 9(25) are limited by s 10(2) to material contribution or aggravation only where the person's diabetes was suffered or contracted before or during (but did not arise out of) relevant service. This can be a technical barrier when diabetes first arises after service and the claimant asserts aggravation.

11. Non‑medical factor: inability to obtain appropriate clinical management. Section 9(25) includes inability to obtain appropriate clinical management for diabetes mellitus as a factor. That factor requires evidence of attempts to obtain management and the nature of barriers. It is qualitative and may be difficult to prove without contemporaneous records.

12. Measurement definitions requiring careful calculation. One pack‑year is defined in the Schedule and was amended (Endnote 4, No. 94 of 2022). The Schedule also supplies a worked example. Claims relying on pack‑year calculations must adhere to that definition, including the conversion of pipe tobacco and cigars by weight.

13. Occupational/environmental exposures with demanding proof burdens. Demonstrating 500 cumulative hours of exposure to TCDD‑contaminated agents, or 5,000 hours of second‑hand smoke, requires workplace or environmental evidence. Vague recollections are unlikely to meet the SOP standard.

14. Death claims require showing diabetes contributed to the terminal event. For death to be within scope, diabetes must have contributed to the terminal event or condition (s 7(5)). That often requires cause of death documentation and expert opinion linking diabetes to the terminal event.

These textual gotchas translate into practical risks: incomplete medical records, imprecise exposure histories, misclassification of diabetes subtype, failure to link exposure to relevant service, and missing cross‑recorded information from other SOPs. Advisers must plan evidence collection to match the instrument's definitional and temporal granularity.

For claimants, advocates and advisers preparing a claim that relies on this Statement of Principles, compliance means assembling evidence that directly maps to the instrument's definitions, thresholds, timing windows and relational rules. The following is a concrete, source‑grounded checklist tied to particular sections and Schedule items.

1. Establish the diagnosis per s 7(2). Obtain and file laboratory records showing either:

   • Two positive tests on separate days with fasting plasma glucose ≥ 7.0 mmol/L; or
   • Two positive tests with plasma glucose ≥ 11.1 mmol/L two hours after a 75 gram glucose load; or
   • Two positive HbA1c results ≥ 6.5 per cent; or
   • Documentation of an episode of diabetic ketoacidosis or hyperosmolar hyperglycaemic state with blood glucose ≥ 11.1 mmol/L (s 7(2)(a)(i)-(ii)). Labels, dates and lab reference ranges should be included to avoid disputes over which tests were performed and when.

2. Identify the diabetes subtype. Determine whether the condition is drug‑induced, gestational, primary, secondary, type 1 or type 2, because s 9 applies different factors by subtype (s 7(2)(b); s 9(6) and s 9(7)). Produce clinical records showing insulin dependence where relevant for type 1, or evidence of insulin resistance/ metabolic syndrome features for type 2.

3. Map claimed factors to s 9. At least one factor must exist (s 9). For each asserted factor, prepare:

   • Documentary proof of the factor's existence (operation reports, transplant records, radiotherapy fields, pathology reports, infection serology, immunotherapy records).
   • Temporal evidence to show the factor occurred in the time windows required (for example, Vacor ingestion within 30 days before onset; immune checkpoint inhibitor or interferon within 1 year; Coxsackie B infection within 3 years for type 1) (s 9(6)(f)-(h)).

4. For drug and steroid exposures, compute cumulative doses and durations in accordance with Schedule definitions:

   • For glucocorticoid therapy as specified, calculate cumulative dose and average daily dose or show equivalent therapy per the Schedule table (Schedule entries for "equivalent glucocorticoid therapy" and "glucocorticoid therapy as specified"). If inhaled therapy is claimed, document daily microgram dosages and durations (Schedule).
   • For Specified List 1 drugs, show that the drug is on the list and that the minimum treatment duration was met (s 9(4); Schedule Specified List 1).
   • For antidepressant or antipsychotic classes, show at least six weeks continuous treatment before clinical onset or worsening (s 9(5) and s 9(13)).

5. Smoking and second‑hand smoke calculations:

   • Use the Schedule's one pack‑year definition to compute pack‑years. Document smoking frequency, duration, and any cessation dates (s 9(7)(a); Schedule "one pack‑year" and explanatory note).
   • For second‑hand smoke, document hours of enclosed‑space exposure and any cessation dates to show whether the 5,000 hour threshold and 15‑year cessation rule apply (s 9(7)(b); Schedule definition of being exposed to second‑hand smoke).

6. Weight and physical activity evidence:

   • For "overweight or obese" claims, supply BMI records over time or waist circumference measures consistent with Schedule thresholds, and show persistence for at least five years if claiming s 9(7)(c) or s 9(23)(c).
   • For inability to undertake moderate physical activity of at least four METs, provide functional assessments, exercise tests, or clinical notes showing the relevant capacity for at least five years (s 9(7)(d) and Schedule definition of MET).

7. TCDD and arsenic exposures:

   • For TCDD contaminated agent exposures, document activities listed in the Schedule (decanting, spraying, handling treated timber, use of contaminated cutting oils, etc.) and show cumulative hours and timing (s 9(7)(s); Schedule).
   • For arsenic exposure, document drinking water concentrations, duration and cumulative exposure metrics required by the Schedule, or clinical evidence of chronic arsenic toxicity (s 9(23)(o); Schedule "being exposed to arsenic as specified").

8. Cross‑referenced SOPs and other conditions:

   • If the asserted factor refers to another SOP, obtain and apply that SOP (s 11). For example, if a factor points to a pancreatic disease covered elsewhere, the other SOP's factors must be satisfied in accordance with s 11.

9. Link factor to relevant service:

   • Under s 10(1) the existence of the factor must be related to the person's relevant service. Collect service records, deployment timelines, occupational exposure reports, unit logs, and contemporaneous medical records showing the nexus between service activities and the claimed exposure or event.

10. For aggravation and material contribution cases, attend to s 10(2):

    • The s 9(9)-(25) factors apply only to material contribution or aggravation where diabetes was suffered or contracted before or during (but did not arise out of) relevant service. If claiming aggravation, provide baseline medical records showing pre‑service or during‑service diabetes status and subsequent worsening.

11. For death claims, obtain cause of death documentation and expert opinion linking diabetes to the terminal event:

    • Because s 7(5) includes death from diabetes where a terminal event or condition was contributed to by the diabetes, secure the death certificate, coronial findings if any, and clinical opinions tying the diabetes to the terminal event listed in the Schedule.

12. Document inability to obtain appropriate clinical management where claimed:

    • If claiming the factor in s 9(25), record attempts to access care, barriers, referrals, waiting lists, or regional capacity limits. That qualitative evidence should be contemporaneous where possible.

13. Provide expert medical nexus evidence:

    • The RMA states that its factors are based on sound medical‑scientific evidence (s 8). In contested cases, an expert medical opinion explaining how the documented factor, within the time window, could cause, contribute to or aggravate diabetes, and how that relates to the person's service, will be necessary.

14. Keep track of version and amendment dates:

    • Use the version of the SOP in force at the time relevant to the claim. The amendment history in the endnotes shows that key provisions were altered in 2021 and 2022 (Endnote 3 and 4). Cite the correct instrument number and commencement date in submissions.

15. Prepare for evidentiary gaps:

    • Where precise dosing or exposure records are missing, assemble corroborative evidence: pharmacy dispensing records, employer logs, unit operational reports, witness statements, and contemporaneous clinical notes that can be used to reconstruct exposure.

16. Cross‑document calculations and units:

    • Ensure unit consistency when calculating doses, pack‑years, hours of exposure, or BMI, using the Schedule's explicit formulas (Schedule BMI = W/H2 and one pack‑year calculation note). Attach worked examples where helpful.

By following this mapping of documentary and expert evidence to the SOP's specific tests, claimants and their advisers give decision makers the discrete elements the instrument requires. The SOP's technical thresholds make precise evidence and careful temporal linkage the key compliance tasks.